ENTITY
Broncus

Broncus (2216 HK)

21
Analysis
Health Care • China
Broncus is a medical device company focused on the research, development, manufacturing, and commercialization of innovative solutions for lung diseases. The company provides diagnostic solutions, lung cancer treatment solutions, and chronic obstructive pulmonary disease (COPD) solutions, including navigation platforms and interventional therapeutic devices like the InterVapor system and BroncAblate. Broncus was founded in 2012 and is headquartered in Hangzhou, China.
more
bearish•Broncus
•23 Sep 2021 11:42

Broncus (堃博医疗) IPO Trading: Chilled for a Reason but Mind the Share Concentration

We look at the updates since our last note for Broncus IPO. We re-iterate our view that the company is fairly valued at the top end and will stay...

Logo
444 Views
Share
bullish•Biel Crystal
•19 Sep 2021 10:10

ECM Weekly (19th September 2021) - PHC, StarHealth, TDCX, Biel Crystal, DRCBank, Transcenta, Broncus

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
638 Views
Share
bearish•Broncus
•15 Sep 2021 16:55

Broncus IPO Valuation: Overly Ambitious

Our reverse DCF suggests that the revenues need to grow at a CAGR of 86.3% in order to justify the implied IPO valuation of HK$7.68bn which seems...

Share
bearish•Broncus
•13 Sep 2021 11:02

Broncus (堃博医疗) IPO: Long Term Faith Needed

We provide an update for the book building of Broncus. The company has an interesting product portfolio but the sales ramp-up will be slow.

Logo
451 Views
Share
bearish•Broncus
•12 Sep 2021 15:25

Broncus (堃博医疗) Pre-IPO: Thoughts on Valuation

We provide key assumptions for the forecast of Broncus' financials and pre-money valuation. The company is fairly valued based on forward EV/Sales...

Logo
483 Views
Share
x